source
- Eli Lilly signs up to $1.9B deal with Ascidian Therapeutics for RNA editing in kidney diseaseAscidian Therapeutics recently presented early data indicating that its novel RNA‑editing approach to repair faulty genes appears safe in humans, focusing on kidney disease applications. Eli Lilly…
- Alnylam commits $30 million upfront to AI startup Inceptive for RNA research collaborationAlnylam Pharmaceuticals announced a new collaboration with Inceptive, a Silicon Valley biotech startup that focuses on RNA. The agreement includes an upfront payment of $30 million and is intended…